Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?. (13th October 2010)

• Record Type: Journal Article
• Authors: McDonnell, Alison M.; Robinson, Bruce W. S.; Currie, Andrew J.
• Other Names: Klinman Dennis Academic Editor.
• Is Part Of: Clinical & developmental immunology. Volume 2010(2010)
• Publication Date: 2010-10-13
• Subjects: Developmental immunology -- Periodicals; Clinical immunology -- Periodicals; Immune System -- immunology -- Periodicals; Immune System -- growth & development -- Periodicals; Immune System Diseases -- immunology -- Periodicals; 571.9638
• DOI: 10.1155/2010/539519
• Languages: English
• ISSNs: 1740-2522

Abstract

Abstract : Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that are critical for the generation of effective cytotoxic T lymphocyte (CTL) responses; however, their function and phenotype are often defective or altered in tumor-bearing hosts, which may limit their capacity to mount an effective tumor-specific CTL response. In particular, the manner in which exogenous tumor antigens are acquired, processed, and cross-presented to CD8 T cells by DCs in tumor-bearing hosts is not well understood, but may have a profound effect on antitumor immunity. In this paper, we have examined the role of DCs in the cross-presentation of tumor antigen in terms of their subset, function, migration, and location with the intention of examining the early processes that contribute to the development of an ineffective anti-tumor immune response.